GT
CTIC

Glenmede Trust’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Glenmede Trust’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-147
Closed – – 2880
2016
Q1 		$0 Hold
147
– – ﹤0.01% 2842
2015
Q4 		$1K Buy
+147
New +$1.96K ﹤0.01% 2618
2015
Q3 		– Hold
0
– – – 2980
2015
Q2 		– Hold
0
– – – 2906
2015
Q1 		– Hold
0
– – – 2673

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Glenmede Trust's CTIC Position: Q2 2016 in Review

Glenmede Trust sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2016, closing a stake of 147 shares.

Glenmede Trust first reported a position in CTIC in Q4 2015 and held it in 2 quarters. The position peaked at $1K in Q4 2015. 67 funds tracked by Wall St. Rank hold CTIC as of Q2 2016.

  • Glenmede Trust reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2016 after selling out during the quarter.
  • Glenmede Trust sold 147 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2016.
  • Glenmede Trust first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2015 and held it in 2 quarters.
  • Glenmede Trust's CTI BioPharma Corp. (DE) Common Stock position peaked at $1K in Q4 2015.
  • 67 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2016.

Based on Glenmede Trust's 13F filing for Q2 2016, filed 5 Aug 2016.